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ABSTRACT
Objective: Evaluation of predictive value of liver
function tests (LFTs) for the detection of liver-related
disease in primary care.
Design: A prospective observational study.
Setting: 11 UK primary care practices.
Participants: Patients (n=1290) with an abnormal
eight-panel LFT (but no previously diagnosed liver
disease).
Main outcome measures: Patients were investigated
by recording clinical features, and repeating LFTs,
specific tests for individual liver diseases, and
abdominal ultrasound scan. Patients were characterised
as having: hepatocellular disease; biliary disease;
tumours of the hepato-biliary system and none of the
above. The relationship between LFT results and disease
categories was evaluated by stepwise regression and
logistic discrimination, with adjustment for
demographic and clinical factors. True and False
Positives generated by all possible LFT combinations
were compared with a view towards optimising the
choice of analytes in the routine LFT panel.
Results: Regression methods showed that alanine
aminotransferase (ALT) was associated with
hepatocellular disease (32 patients), while alkaline
phosphatase (ALP) was associated with biliary disease
(12 patients) and tumours of the hepatobiliary system
(9 patients). A restricted panel of ALT and ALP was an
efficient choice of analytes, comparing favourably with
the complete panel of eight analytes, provided that 48
False Positives can be tolerated to obtain one additional
True Positive. Repeating a complete panel in response
to an abnormal reading is not the optimal strategy.
Conclusions: The LFT panel can be restricted to ALT
and ALP when the purpose of testing is to exclude liver
disease in primary care.
INTRODUCTION
Liver function tests (LFTs) are inexpensive
tests that are frequently ordered in a panel
of up to eight analytes as a ‘test of exclusion’
in patients with non-speciﬁc symptoms or as
part of routine health checks. LFTs are difﬁ-
cult to study because the tests portend a very
large number of diseases, some of them very
rare. Nevertheless, there is a large literature
on LFTs; a review by Green and Flamm
located 6000 papers published since 1990
alone.1 However, this literature mostly origi-
nates from hospital practice and often deals
with a restricted number of analytes.
Moreover, it is predominantly retrospective
and concerned with the probabilities of test
results given the disease-state, whereas the
ARTICLE SUMMARY
Article focus
▪ The response to an abnormal liver function test
(LFT) result in primary care is highly eclectic.
▪ Guidelines suggest repeating an abnormal stand-
ard LFT panel.
▪ We conducted a prospective study to evaluate
the prognostic value of LFTs.
Key messages
▪ The prevalence of significant liver disease in
people with incidental abnormal LFTs is little
higher than the population prevalence.
▪ The policy of requesting a standard LFT panel
with a view to repeating it if abnormal is
inefficient.
▪ Just two analytes (alanine aminotransferase and
alkaline phosphatase) provide an efficient default
testing strategy for excluding liver disease (of
viral, genetic, autoimmune or neoplastic origin)
in primary care.
Strengths and limitations of this study
▪ This is the first large, prospective primary care-
based study of patients with abnormal LFTs that
were fully evaluated for liver disease.
▪ Patients where all analytes were normal were not
included, meaning that while True and
False-Positive rates are unbiased, sensitivity and
specificity may be overestimated and underesti-
mated, respectively.
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clinician typically starts with the LFT result and needs to
know the predictive probability of the disease. An
updated review of the literature2 shows that there are no
prospective studies based in primary care practice where
patients were fully investigated following at least one
abnormal analyte from a full LFT panel. It is therefore
not surprising that eclectic decision-making has been
documented in primary care.3 Birmingham and
Lambeth Liver Evaluation Testing Strategies (BALLETS)
was a prospective UK study that aimed to assess the
value of abnormal LFT analytes for predicting signiﬁcant
liver disease in primary care. The detailed report of the
study will appear in the Health Technology Assessment
(HTA) monograph series.2 Here, we use the study infor-
mation to investigate the diagnostic potential of LFT
results, taking account of the individual patient charac-
teristics, and examine the positive predictive perform-
ance of different LFT panels for the diagnosis of liver
disease using standard laboratory-based reference ranges
that inform general practitioner (GP) decision-making.
We consider viral, genetic and autoimmune diseases and
tumours of the hepatobiliary system; a discussion of fatty
liver will appear in the HTA report.2
METHODS
BALLETS study
Data collection
BALLETS was a prospective UK study of patients with an
abnormal LFT panel across eight primary care practices
in Birmingham and three in the Lambeth area of
London. The 11 practices were served by three labora-
tories following similar analytical procedures, one of
which accounted for over 80% of the sample.2 Patients
were eligible for the study if they did not have obvious
or pre-existing liver disease, and one or more of the
eight analytes in an index LFT panel was abnormal. We
set out to recruit 1500 such patients on the grounds that
this would allow us to examine the predictive perform-
ance for liver disease of up to 12 variables without over-
ﬁtting using a 10 to 1 ‘events per variable’ rule. This cal-
culation was supported by computing the chance of
missing high-risk cases when using a logistic discriminant
function based on LFTs.2 The index panel comprised:
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), γ-glutamyltransferase (GGT), bilirubin
(Bili), alkaline phosphatase (ALP), albumin (Alb),
globulin (Glob), and total protein (Tprot).4 Analyte
abnormality was determined using standard laboratory
reference ranges, which are routinely adjusted for age
and gender where appropriate.2
Recruitment took place from 2005 to 2008. Eligible
patients were invited to join the study and attend a ﬁrst
follow-up session (FU1) at the practice where the follow-
ing data were collected:
1. Patient and clinical characteristics, including age, sex,
ethnic group, country of birth, reason for blood
testing, medication and history of illness, substance
abuse, travel, immunisation and transfusion history;
2. Alcohol use, via a standardised questionnaire2;
3. Weight, height, waist and hip circumference
measurements;
4. Repeat of the eight-analyte LFT panel;
5. Blood for speciﬁc (auto-immune, genetic and viral)
diseases in the ‘liver work up’ (table 1);
6. Ultrasound scan (USS) of the upper abdomen. Any
tumours of the hepatobiliary system were noted and
the liver was classiﬁed as normal, echobright (in
three levels of intensity) or cirrhotic. A sample of
ultrasound ﬁlms were reviewed by the study
radiologist.
The research team produced a consolidated report
comprising the results of the index LFT panel and the
information collected from follow-up. The patient then
attended the primary care practitioner for a consultation
informed by the consolidated report. Participating
primary care practitioners were provided with a set of
guidelines2 to assist in future decision-making when one
of the tests in table 1 was abnormal, or when an abnor-
mality was seen on USS. Primary care practice and hos-
pital records were reviewed by the research team to
harvest information gleaned from follow-up tests.
Primary care practitioners were alerted if follow-up inves-
tigations had not been carried out when indicated.
Diagnostic categories
The number of diseases that might cause abnormal LFT
results is very large. This issue was tackled by grouping
the diseases into categories that made sense clinically
and pathophysiologically (table 1). These were:
1. Hepatocellular disease
2. Biliary disease
3. Tumours of the hepatobiliary system
All other patients were placed in a ‘non-speciﬁc’
category.
Follow-up
The BALLETS cohort was followed up by examination
of the primary care and hospital records and a follow-up
visit after 2 years (FU2), where clinical examination
(repeat LFTs and abdominal ultrasound) was repeated.
The results of the 2-year follow-up are included in the
full report.2
Analytical approach
Exploratory analysis of analyte concentrations
A hierarchical stepwise approach was used to investigate
between-patient variation in each of the eight analyte
concentrations in the FU1 panel, log-transformed to
improve distributional symmetry. All analyses were
adjusted for laboratory effects. First, the log-
concentration was described by a linear (analysis of vari-
ance) model using the main effects of age, sex, ethnic
group, body mass index (BMI) and alcohol
2 Lilford RJ, Bentham LM, Armstrong MJ, et al. BMJ Open 2013;3:e003099. doi:10.1136/bmjopen-2013-003099
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consumption (table 2) together with all two-way interac-
tions involving age or sex. Backwards elimination was
applied ﬁrst to remove non-signiﬁcant (p>0.05) interac-
tions and then to remove non-signiﬁcant main effects
from the model, with the provisos that the main effects
of age and sex, and the age-by-sex interaction were
always retained, and that no main effect was removed if
it featured in a signiﬁcant interaction. The threshold for
Table 2 Baseline patient characteristics (N=1290)
Reason for
testing
Signs and
Symptoms
406 (31.5)
Chronic disease
review
884 (68.5)
Sex Male Female
724 (56.1) 566 (43.9)
Age (years) ≤34 35–44 45–54 55–64 65–74 75+
106 (8.2) 165 (12.8) 240 (18.6) 325 (25.2) 273 (21.2) 181 (14.0)
Ethnic group White Asian Black Other Not known
1056 (81.9) 89 (6.9) 66 (5.1) 40 (3.1) 39 (3.0)
Country of
birth
UK Indian
Subcontinent
Other
countries
Not known
1022 (79.2) 60 (4.7) 180 (14.0) 28 (2.2)
BMI at FU1
(kg/m2)
<20 20–24.99 25–29.99 ≥30 Not known
49 (3.8) 250 (19.4) 454 (35.2) 498 (38.6) 39 (3.0)
Alcohol at FU1
(units/week*)
0 1–14 15–29 30–49 50–99 100+ Not known
547 (42.4) 352 (27.8) 153 (11.9) 122 (9.5) 84 (6.5) 24 (1.9) 8 (0.6)
Entries are frequencies (and per cent of total).
*1 unit=10 g of alcohol, FU1: follow-up visit 1.
BMI, body mass index.
Table 1 Liver disease (viral, genetic and autoimmune) for which all patients were tested*
Category Disease
Blood tests carried out on all
members of the cohort (to
diagnose or screen for the
disease)
Method by which diagnosis was
made in screen positive cases
Hepatocellular
diseases
Chronic viral hepatitis C Hepatitis C virus antibody (HCV
Ab)
Viral marker positive and
hepatologist’s opinion
Chronic viral hepatitis B Hepatitis B surface viral antigen
(HBV surface Ag)
Viral marker positive and
hepatologist’s opinion
Metal storage disease: Iron
(haemochromatosis)
Transferrin levels Genotype performed on patient if
transferrin saturation >50%
Autoimmune hepatitis Smooth muscle antibody Raised antibodies and ALT or AST or
globulin exceeding twice the upper
limit of normal. Confirmed by the
hepatologist’s opinion
Metal storage disease:
Copper (Wilson’s disease)
Caeruloplasmin Low levels of caeruloplasmin and
hepatologist’s opinion
α-1 Antitrypsin (A1AT)
deficiency
A1AT level Phenotype testing performed if A1AT
abnormal
Alcoholic/fat-induced
cirrhosis or hepatocellular
cancer (HCC)
N/A Abdominal ultrasound+exclusion of
other diseases in this table and
hepatologist’s opinion
Intrahepatobiliary
duct disease
Primary biliary cirrhosis
(PBC)
Antimitochondrial antibody Anti-mitochondrial antibodies (≥1:40
titre) and hepatologist’s opinion
Primary sclerosing
cholangitis
N/A Combination raised ALP and
ulcerative colitis. Confirmed by
hepatologist’s opinion
Previously undiagnosed cirrhosis of other causes was also included in this category.
*We did not include the benign condition Gilbert’s syndrome in any disease category.
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exclusion was set relatively high (p>0.05), which tends to
increase the explained variation in LFTs, thus reducing
the risk of ﬁnding marginal differences between diag-
nostic groupings that could be attributed to patient char-
acteristics. These analyses were conﬁned to patients for
whom a complete set of patient characteristics had been
recorded (N=1211). Finally, the marginal impact of the
diagnostic category was investigated by adding factors
representing the ﬁve diagnoses of: viral hepatitis; other
hepatocellular disease; biliary disease; hepato-biliary
tumour and non-speciﬁc.
Diagnostic potential
Analyte concentrations were ﬁrst scaled to the laboratory
that performed the largest proportion of tests (78%),
using factors estimated in the exploratory analysis.
Stepwise logistic regression was used to determine the
best combinations of patient characteristics and (scaled)
analyte concentrations to distinguish between the non-
speciﬁc diagnostic group and each of the three main
liver disease groups in separate analyses. The analysis
was repeated for a subcategory of hepatocellular disease,
viral hepatitis, because of its clinical importance. The
candidate variables were: age, sex, ethnic group, BMI,
country of birth and all eight analyte concentrations
(logged) from the FU1 follow-up panel. Interactions
were not considered. Missing values in all candidate vari-
ables were handled using the chained equation method
in Stata V.12.5 Signiﬁcant predictors were identiﬁed
using four complementary procedures: backward elimin-
ation, with a p>0.01 threshold for exclusion from the
model; forward selection, with p<0.01 for inclusion and
two mixed forward and backward procedures with
p>0.01 for exclusion and p<0.005 for inclusion.
Comparison of index panels for liver disease diagnosis
The absence of patients with completely normal analyte
concentrations in the index sample (as determined by
conventional reference ranges) precludes a comprehen-
sive analysis of the diagnostic performance of LFTs.
Positive predictive performance was addressed using the
laboratory-based reference ranges commonly used in
general practice, though it is impossible to consider the
impact of relaxing the thresholds for abnormality in this
data set. The analysis considers the 255 (=28–1) possible
index LFT panels that can be constructed from eight
analytes and is conﬁned to the 915 patients with index
measurements on all eight analytes. For a particular
patient, a panel was considered to be positive if at least
one analyte concentration fell outside its reference
range. A positive panel was characterised as a True
Positive (TP) or False Positive (FP) according to whether
it belonged to a patient with or without liver-related
disease, deﬁned broadly to include all serious diseases
(hepatocellular, biliary and tumours of the hepatobiliary
system (categories 1, 2 and 3)). One panel dominates
another if it generates more TPs and fewer FPs.
Otherwise, preference between two panels can be
determined if the trade-off between the value of a TP
and the cost of an FP is speciﬁed. A panel with more
TPs and FPs than another panel will be preferred if the
ratio of the extra TPs to FPs generated is more than the
trade-off value. For example, if the TP/FP trade-off is
0.01, then ﬁnding one extra TP can compensate for
incorrectly identifying up to 100 extra FPs. SEs for the
ratios of extra TPs and FPs for comparing pairs of
panels, and for the Positive Predictive Values (PPVs) of
individual panels, were obtained from 1000 bootstrap
resamples from the original 915 patients.
Treatment of missing data
The analysis of alternative index panels is restricted to
patients with a complete set of eight index analytes.
Including incomplete panels here would mean that the
yield (total number of positives) from a subpanel of
fewer than eight analytes would be biased upwards,
since some patients would owe their presence in the
study to abnormalities on just those analytes (and no
others). Nevertheless, restriction to complete index
panels cannot eliminate all recruitment biases since it
favours those practices where the GPs have applied the
study protocol most attentively. The analytical choices
have been made, to some extent, on pragmatic grounds.
Thus, the exploratory regression and discriminant ana-
lyses of the FU1 panel have been applied to all patients
in order to maximise coverage. In any case, the potential
for bias is reduced here because of the imperfect correl-
ation between index and follow-up tests, and because
the analysis does not refer explicitly to the thresholds of
abnormality that triggered recruitment to the study.
Incompleteness in FU1 panels is uninformative since it
results from the laboratory’s failure to report rather than
the GP or patient’s non-compliance.
RESULTS
Patients and data
The study sample of 1290 patients is summarised in
table 2. Index panels were available for all 1290 patients,
of which 915 (70.9%) included all eight analytes. The
FU1 panel was taken after a median of 30 days postindex
(IQR 21–51). There were 1275 patients (98.8%) with an
LFT panel at follow-up, of which 1168 (92%) were com-
plete. Eighty-ﬁve per cent (992/1168) of complete FU1
panels had an abnormal LFT, falling slightly to 84%
(706/844) where the index panel was also complete.
The correlation between index and follow-up tests was
high for all analytes, ranging from 0.66 for Tprot to 0.89
for GGT. Hence, the initial level of abnormality has a
marked inﬂuence on the probability that an abnormal
analyte will revert to normal on repeat testing. The ﬁve
non-protein analytes (ALT, AST, Bili, ALP, GGT) all
showed a reduction over time that might be interpreted
as a regression to the mean (table 3).
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Table 3 Analyte concentrations and abnormalities by diagnostic category
Analyte (units) Panel N Median IQR
Abnormalities by diagnostic category: number abnormal/number tested (%)
Total
(N=1290)
Non-specific
(N=1237)
Category 1
(N=32)
Category 2
(N=12)
Category 3
(N=9)
ALT
(U/l)
Index 1114 34 (22–52) 438/1114 (39.3) 415/1071 (38.8) 18 /27 (66.7) 3/8 (37.5) 2/8 (25.0)
FU1 1234 31 (22–46) 375/1234 (30.4) 346/1184 (29.2) 23/30 (76.7) 3/11 (27.3) 3/9 (33.3)
AST
(U/l)
Index 1158 29 (23–40) 255/1158 (22.0) 237/1108 (21.4) 14/29 (48.3) 3/12 (25.0) 1/9 (11.1)
FU1 1212 28 (23–37) 172/1212 (14.2) 153/1163 (13.2) 15/30 (50.0) 3/11 (27.3) 1/8 (12.5)
Bili
(μmol/L)
Index 1265 9 (7–13) 148/1265 (11.7) 142/1213 (11.7) 5/31 (16.1) 1/12 (8.3) 0/9 (0.0)
FU1 1233 9 (6–13) 111/1233 (9.0) 106/1185 (9.0) 3/29 (10.3) 1/11 (9.1) 1/8 (12.5)
ALP
(U/l)
Index 1272 188 (144–247) 189/1272 (14.9) 172/1220 (14.1) 5/31 (16.1) 9/12 (75.0) 3/9 (33.3)
FU1 1236 187 (142–238) 143/1236 (11.6) 130/1188 (10.9) 4/29 (13.8) 7/11 (63.6) 2/8 (25.0)
GGT
(U/l)
Index 1152 64.5 (44–104) 867/1152 (75.3) 833/1108 (75.2) 18/28 (64.3) 8/8 (100.0) 8/8 (100.0)
FU1 1243 58 (37–98) 787/1243 (63.3) 749/1193 (62.8) 20/31 (64.5) 9/10 (90.0) 9/9 (100.0)
Alb
(g/l)
Index 1278 45 (43–47) 30/1278 (2.4) 29/1225 (2.4) 1/32 (3.1) 0/12 (0.0) 0/9 (0.0)
FU1 1254 46 (44–48) 40/1254 (3.2) 36/1206 (3.0) 4/29 (13.8) 0/11 (0.0) 0/8 (0.0)
Glob
(g/l)
Index 977 29 (27–32) 55/977 (5.6) 53/938 (5.7) 2/23 (8.7) 0/8 (0.0) 0/8 (0.0)
FU1 1214 30 (27–33) 74/1214 (6.1) 66/1167 (5.7) 4/28 (14.3) 3/11 (27.3) 1/8 (12.5)
Tprot
(g/l)
Index 981 74 (71–77) 97/981 (9.9) 93/942 (9.9) 4/23 (17.4) 0/8 (0.0) 0/8 (0.0)
FU1 1235 76 (73–79) 199/1235 (16.1) 187/1185 (15.8) 9/30 (30.0) 2/11 (18.2) 1/9 (11.1)
FU1: follow-up visit 1 (mean of 30-day postindex bloods).
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bili, bilirubin; GGT, γ-glutamyltransferase; Glob, globulin; Tprot, total protein.
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Prevalence of disease in the cohort
Hepatocellular diseases were present in 32 cases (2.5%)
and biliary disease in 12 cases (0.9%). Viral hepatitis B
or C was the most common hepatocellular disease (13
cases, all subsequently treated), followed by haemo-
chromatosis (four compound heterozygote and six
homozygous, of whom four were treated by regular
venesection), cirrhosis (six cases, including one case of
hepatoceullular carcinoma) and α 1-antitrypsin deﬁ-
ciency (three cases). Biliary diseases comprised Primary
Biliary Cirrhosis (10 cases) and Primary Sclerosing
Cholangitis (two cases). Tumours of the hepatobiliary
system (nine cases) were metastatic liver cancer (four
cases), cancer of the pancreas or bile duct (four cases)
and amoebic liver abscess (one case).
Analyte concentrations, patient characteristics and
disease category
The results of the stepwise regressions are summarised
in table 4. The main effects and interaction for Age and
Sex were included, by design, in all base models. The
relationship with BMI was signiﬁcant for all analytes
except ALP, and varied with age except in the case of
Bili. The effect of alcohol was signiﬁcant for ALT, AST
and GGT. The ethnic group impacted on protein ana-
lytes most markedly on Glob levels, which were raised in
non-white groups (see the main report for fuller
details).2 The impact of disease categories is presented
in terms of multiplicative factors applied to the analyte
concentrations (table 4). Signiﬁcant effects are evident
for ALT and AST (both raised in hepatocellular disease);
ALP (raised in biliary disease and tumours of the hepa-
tobiliary system); GGT and Glob (raised in biliary
disease) and Alb (reduced in tumours).
Diagnostic potential
For both the biliary disease and hepatobiliary tumour cat-
egories, all four stepwise procedures converged to the
same single diagnostic indicator, namely ALP, with no
other analytes or patient characteristics retained in the
models. The associated c-statistics were 0.84 for biliary
disease and 0.83 for hepatobiliary tumours. For the diag-
nosis of hepatocellular diseases, ALTand ASTemerged as
alternative diagnostic markers, depending on the details
of the stepwise procedure. The alternative models were
ALT with BMI (c-statistic 0.80) and AST with Country of
Birth (c-statistic 0.76). When the viral hepatitis subgroup
was considered as a separate category, Country of Birth
featured in all models, alongside one or the other of
these two analytes with similar c-statistics 0.92 (ALT with
Country of Birth) and 0.89 (AST with Country of Birth).
A further analysis was performed, contrasting non-
hepatitis hepatocellular disease with the non-speciﬁc
group. Here, AST and ALT again emerged as alternatives,
with near identical c-statistics (=0.76 to 2 dp), but no
other variables were retained by any of the four stepwise
procedures. Thus, only three analytes featured in the
individual diagnostic models: ALT, ASTand ALP.
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Performance of alternative LFT panels
The numbers of TPs and FPs are plotted in ﬁgure 1 for
each of the 255 possible LFT panels. The set of panels
that are not dominated by any other panel is well
approximated by the frontier in ﬁgure 1, deﬁned by
three panels involving just three analytes, ALP, ALP with
ALT, and ALT with GGT. Of these, ALT and ALP arose as
likely diagnostic candidates from the discriminant ana-
lyses, and GGT as the analyte with the highest overall
positive rate (75.3%). The slopes of the line segments
between the panels on the frontier (ie, ratio of extra
TPs to extra FPs) are (ALP) to (ALP with ALT), 0.059
(SE 0.014); (ALP with ALT) to (ALT with GGT), 0.022
(SE 0.008). Thus, the single analyte panel (ALP) would
be preferred so long as a TP is worth no more than the
cost of approximately 17 FPs (=1/0.059); and the
two-analyte panel (ALP with ALT), if this is more than
17 but less than 45 (=1/0.022). The analyte GGT (in
combination with ALT) is not indicated unless the value
of a TP is even higher. Furthermore, the slope of the
line between (ALP with ALT) and the full panel is 0.021
(SE 0.007), suggesting that the full panel offers no
enhancement unless the value of a TP is around 48
times the cost of an FP. The estimated PPVs for the
panels on the frontier range from 8.7% (SE 2.8%) for
ALP alone, through 6.3% (SE 1.2%) for ALP and ALT,
to 4.4% (SE 0.7%) for ALT and GGT. The PPV of the
eight analyte panel is 4% (SE 0.7%).
In the light of the results of the discriminant analysis,
AST might be considered as an alternative to ALT in the
construction of candidate panels. Indeed, the panels AST
(PPV=7%, SE 2%) and (AST with ALP) (PPV=7.1%, SE
1.9%) generate similar PPVs to ALT and (ALT with ALP),
respectively; but the overall yield, that is, total numbers of
positives, is much reduced compared with the ALT ver-
sions. The panel (ASTwith ALP) generates only 257 posi-
tives compared with 429 for (ALTwith ALP).
Repeat testing
The effect of repeat testing is also shown in ﬁgure 1.
Here, it can be seen that repeating the full panel is an
inefﬁcient strategy achieving, for example, results similar
to a single administration of a two-analyte panel (ALT
with GGT; ﬁgure 1).
Effect of increasing the thresholds of abnormality
The full diagnostic value of individual analytes may not be
captured by reference to conventional thresholds of abnor-
mality. The effect of increasing these thresholds is investi-
gated in ﬁgure 2 for the four analytes (GGT, ALT, AST,
ALP) contributing the greatest numbers of positives in the
LFT panel. For three of these (ALT, AST, ALP), the curves
in the corresponding panels of ﬁgure 2 lie clearly above
the diagonal line, showing that the ratio of TPs to FPs rises
as the threshold increases. This entails an increase in PPV
and is to be expected for markers that carry diagnostic
information. For GGT, the ratio of TPs to FPs remains
effectively constant as the threshold increases even to twice
the conventional limit, rising only as it approaches a three-
fold increase. The effect of relaxing thresholds of abnor-
mality cannot be determined given that entry to the study
was based on conventional thresholds.
DISCUSSION
Principal findings
Our prospective study highlights the need to rethink the
role of LFTs in primary care in the absence of obvious
or pre-existing liver disease. First, the prevalence of sig-
niﬁcant liver disease in people with incidental abnormal
LFTs in primary care is little higher than the general
population prevalence (see below, Meaning of the Study
and Clinical Implications). Second, repeating the full
panel of LFTs is an inefﬁcient strategy in primary care.
Lastly, the results have potentially radical implications
for the LFT panel in that selecting just two analytes
(ALT and ALP) is an efﬁcient strategy when the motiv-
ation for testing is the exclusion of signiﬁcant liver
disease: ALT is independently associated with speciﬁc
hepatocellular diseases, while ALP is associated with
biliary diseases and tumours.
Strengths and weaknesses of the study
BALLETS is a unique prospective study in that it com-
prised patients who presented in primary care with a
Figure 1 Positive diagnoses from different index panels.
Split between the non-specific category (False Positives) and
the pooled disease categories 1, 2 and 3 (True Positives). All
255 possible panels from the eight analytes are shown for the
915 patients with complete Index data. Single analyte panels
(open circles) and the complete panel of eight analytes
(diamond) are identified. The frontier (solid circles joined by
line segments) shows the best diagnostic performance that
can be attained using the analytes alkaline phosphatase
(ALP), alanine aminotransferase (ALT) and
γ-glutamyltransferase (GGT). The 2-analyte panel (ALP with
aspartate aminotransferase (AST)) is also shown (open
square). Results from repeating a panel at follow-up if it is
positive initially are indicated by the letter ‘R’, joined by an
arrow to the initial panel.
Lilford RJ, Bentham LM, Armstrong MJ, et al. BMJ Open 2013;3:e003099. doi:10.1136/bmjopen-2013-003099 7
Strategies for investigating abnormal liver function tests
 group.bmj.com on April 1, 2014 - Published by bmjopen.bmj.comDownloaded from 
history of liver disease, who were then comprehensively
screened for liver disease and followed up for 2 years.
The comprehensive screening ‘compressed’ future years,
bringing forward diseases that might otherwise have pre-
sented only decades later. Documentation of clinical
factors enabled analytes that were independently asso-
ciated with various disease categories to be identiﬁed. In
principle, this study can provide unbiased estimates of
PPV of the LFT panel. However, when considered as a
sample from a natural population, it is subject to selec-
tion bias since an abnormal Index LFT was a criterion
for entry to the study. Consequently, attempts to
measure the sensitivity or speciﬁcity of any particular
combination of analytes will lead to biased estimates,
despite the presence of normal analytes in the panel;
sensitivities would be overestimated and speciﬁcities
underestimated. Negative predictive value could not be
measured. Evaluation of LFTs presents particular meth-
odological challenges because, in contrast to the more
usual one test/one disease scenario, up to eight analytes
are involved and these may portend a large number of
diseases. We dealt with the issue of many uncommon dis-
eases by grouping them into clinically and pathologically
meaningful categories, and the issue of multiple analytes
by investigating the diagnostic capacity of all possible
combinations leading to the ‘frontier’ in ﬁgure 1.
Patients could only enter the BALLETS study when
invited to do so by their GP. As part of the study, a
sample of non-participating patients was compared with
participants with respect to demographic features and
severity of baseline abnormality. There was a small
excess of older patients and patients with an abnormal
GGT among those who participated in the study, but
there was no difference in the degree of abnormality
across these groups, suggesting that recruitment biases
induced by GP behaviour are likely to be small.2
Strengths and weaknesses in relation to other studies
Previous primary care studies in the UK have been
limited by their retrospective design,3 6 in that identiﬁca-
tion of signiﬁcant liver disease was dependent on investi-
gations selected by the clinician and/or on review of
hospital-based records. A recent record-linkage study6
followed patients for a median of 3.7 years but without a
full clinical investigation of the cohort. It reached
similar conclusions with respect to the low overall pre-
dictive value of the LFT panel but ascribes greater
importance to GGT than we have performed. However,
the inﬂuence of selection effects on this conclusion
cannot be discounted since GGT measurements were
available for only 11% of the study sample.
The largest prospective data set outside the UK comes
from the Dionysos study (n=6917), which was under-
taken in two towns in northern Italy in the 1990s.7
Although the study provided invaluable data on the
prevalence of liver disease in a general (European)
population, it could not extrapolate on the diagnostic
performance of the full LFT panel currently being uti-
lised by GPs, as only AST, ALT and GGT were collected.
In contrast, our study provides unique information on
individuals who are already engaging with local
UK-health services (for a variety of health problems),
Figure 2 The effect of increasing the threshold of abnormality for four analytes. Numbers of True Positives (ie, patients in
categories 1, 2 or 3 with analyte concentration above the threshold) are plotted against numbers of False Positives, using
thresholds set at fixed multiples of the current laboratory reference limit. Points are plotted at intervals of 0.1 up to twice the
reference limit, and at 3, 4 and 5 times the limit. Points at 1, 1.5, 2 and 3 times the limit are labelled accordingly.
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and thus the ﬁndings have instant ramiﬁcations for opti-
mising the use of LFTs and preventing unnecessary
investigations/repeat testing in primary care.
Meaning of the study and clinical implications
The PPV of the full LFT panel for speciﬁc disease affect-
ing the liver/biliary tract is low in primary care. Less
than 5% of people with an abnormal LFT panel had a
speciﬁc liver disease and 1.7% needed specialised treat-
ment (antiviral therapy or venesection for haemo-
chromatosis). These ﬁndings are corroborated by the
results of a recent record-linkage, which looked at PPV
for mortality.8 The prevalence of viral hepatitis and
homozygous haemochromatosis (the most common cat-
egories of hepatocellular disease) in people with inci-
dental abnormal LFTs was very close to population
norms in England: 1% vs 0.7% and 0.5% vs 0.5%,
respectively.9–12 PPVs would most likely be higher in set-
tings where liver disease, especially hepatitis B and C, is
more common13 (as in the Dionysos study). All but two
cases of chronic viral hepatitis originated in
moderate-risk to high-risk countries. If all such patients
were screened (ie, HBsAg and HCV) when they ﬁrst
registered with a GP in the UK, the predictive values of
LFTs would be lower still. We also considered a small
number of diseases (discovered by reviewing case notes
at 2-year follow-up) that could have affected LFT results
(one case of Lyme disease, one of chronic pancreatitis
and four cases of hypothyroidism). Including these six
cases in the liver disease group leaves the ﬁndings essen-
tially unchanged.2 Figure 2 shows that the TP rate could
be increased by raising the threshold of abnormality, but
at the expense of the total number of TPs. We discuss
the ﬁndings of the BALLETS study with respect to the
enigmatic condition of fatty liver elsewhere.2 14
Selection of analytes
Our results suggest that the functions of a routine LFT
panel can be largely subsumed into just two analytes:
ALT and ALP. Furthermore, ALT and ALP contain infor-
mation pointing towards deﬁnitive diagnosis, in that the
former portends hepatocellular disease and the latter
the biliary disease and tumours of the hepatobiliary
system categories. In keeping with our results, Donnan
et al’s6 record linkage study highlighted that GGT had a
high FP rate (ﬁgure 1). Our study casts further doubt
on the clinical relevance of GGT by the ﬁnding that the
PPV of an abnormal result (unlike those for ALT and
ALP) does not demonstrate the expected increase when
a higher threshold of abnormality is used (ﬁgure 2).
Analytes apart from ALT and ALP should nevertheless
be reserved for particular circumstances; for example,
GGT and AST may be useful when it is suspected that a
patient is in denial about alcohol intake, while Bili has a
role when Gilbert’s syndrome or acute hepatitis A is
suspected.2
Repeat testing
There is a natural impulse to repeat a positive test to see
if it is conﬁrmed and this is the course of action recom-
mended in current guidelines.3 15–18 However, the results
of the study show that this is an inefﬁcient strategy when
a full eight-analyte LFT panel is used in primary care
when the sole purpose is to exclude signiﬁcant liver
disease in the absence of clinical signs. The impact of any
test depends on events triggered downstream of the test
itself.19 20 The decision tree required to model the conse-
quences of the full range of abnormal LFTs would be for-
biddingly extensive and require untested assumptions
such as the effect of various test results on unhealthy
behaviours.2 In a previous study, we modelled the cost-
effectiveness of various strategies for the diagnosis of one
serious treatable disease, chronic viral hepatitis, when the
full index LFT is abnormal. It turns out that it is more
efﬁcient to test directly for the virus than to repeat the
full liver panel with a view to viral testing if an abnormal-
ity persists. Performing a full panel LFT, with a view to
repeating it if abnormal, was the least efﬁcient option
considered.13 Although conducted with respect to a par-
ticular condition (viral hepatitis), this ﬁnding provides
indirect support for the more general proposition that
performing LFTs with a view to repeating them if abnor-
mal is not the optimum strategy.
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